U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known Substitute for form 1449A/PTO 10/599,221 Application Number April 29, 2008 INFORMATION DISCLOSURE Filing Date First Named Inventor Kazuei IGARASHI, et al. STATEMENT BY APPLICANT 1657 Art Unit (Use as many sheets as necessary) Examiner Name to be assigned 075954-010400 Sheet 1 Attorney Docket Number

	U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number-Kind Code ² (if known)	MM-DD-YYYY			
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Foreign Patent Document	Publication Date		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	π5
Initials*	No.1	Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document		ľ
		WO 00/03711	01-27-2000	Tracey, et al.		
		JP 2002-520360	07-09-2002	The Picower Institute for Medical Research		
		JP 2002-181820	06-26-2002	Ikagaku, KK		
		JP 2002-281999	10-02-2002	Igarashi		
	ļ					_
	\vdash					\top

Examiner Signature		Considered	
*EXAMINER:	Initial if reference considered, whether or not citation is in conformance with MPEP 609.	Draw line through	citation if not in conformance and not

considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspion or MPEP 90.104. *Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required by obtain or retain a benefit by the public which is to file (and by the USFTO to process) an application. Confidentiality is governed by 35 U.S. C. 1.22 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USFTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chiffornation Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND.

Approved for use through 07/31/2012, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Unr	ter the Paperwork Reduction Act of 19	95, no persons are required	i to respond to a collection of informa	respond to a collection of information unless it contains a valid OMB control number			
Substitute for form 1449B/PTO			Complete if Known				
3	ubstitute for form 14485/FTO		Application Number	10/599,221			
- 11	NFORMATION DISC	LOSURE	Filing Date	April 29, 2008			
-	STATEMENT BY APPLICANT		First Named Inventor	Kazuei IGARASHI, et al.			
•	MAILMENT DI A	LIOAIII	Art Unit	1657			
	(Use as many sheets as r	ecessary)	Examiner Name	to be assigned			
neet	2	of 2	Attorney Docket Number	075954-010400			

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.1	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²	
	001	SHARMIN, et al., "Polyamine Cytotoxicity in the Presence of Bovine Serum Amine Oxidase", Biochemical and Biophysical Research Communications 282, 228-235 (2001)		
	002	BRUCKMANN, et al., "Spermidine: A Predictor for Neurological Outcome and Infarct Size in Focal Cerebral Ischemia", <i>Stroke</i> (Journal of the American Heart Association) 2001:32,43-46		

LA 128.367.234v1

Examiner Signature	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.41. This collection is entire to be close to be complete, including gathering, preparing, and submitting the completed application form to the USPTO. The will wary depending upon the individual case, Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.